Abstract
Twenty-one patients with nonresectable refractory meningiomas were registered on a study giving tamoxifen 40 mg per M2 b.i.d. for four days, then 10 mg b.i.d. thereafter. Nineteen were eligible and evaluated for response. One patient (5%) achieved an MRI-documented partial response while two had a minor response measured on CT scan which was of short duration (4 and 20 months). Six patients (32%) remained stable for a median duration of 31 + months while ten (53%) demonstrated progression. Twenty-two percent (22%) reported subjective improvement though this did not correlate with objective improvement in all cases. At present, a definite recommendation for the use of tamoxifen in refractory meningiomas cannot be made. Further evaluation of hormonal therapy of meningiomas with a concensus for definition of endpoints for evaluation of response in view of the difficulty of evaluating radiologic findings with clinical outcome, is needed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mahaley MS Jr, Mettlin C, Notarajan N, Laws ER Jr, Peace BB: National survey of the patterns of care in brain tumor patients. J Neurosurg 71: 826–836, 1989
Black P: MCL, Brain tumors. N Engl Journ Med 3322.22: 1555–1564, 1991
Taylor BW Jr, Marcus RB Jr, Friedman WA, Ballinger WE Jr: The meningioma controversy: post-operative radiation therapy. Intern Journ Radiat Oncol Biol Phys 15.2: 299–304, 1988
Schereil UM, Adams EF, Fahlbusch R, Greb R, Jirikowski G: Hormonal dependance of cerebral meningiomas. Part I: female sex receptors and their significance of specific markers for adjuvant medical therapy. Journ Neurosurg 75.5: 743–749, 1990
Lesch KP, Gross S: Estrogen receptor immunoreactivity in meningiomas. Comparison with the binding activity of estrogens, progesterones and androgen receptors. Journ Neurosurg 67.2: 237–243, 1987
Grunberg SM, Daniels AM, Muensch H, Daniels JR, Bernstein L, Kortes V, Weiss MH: Correlation of meningioma hormone receptor status with hormone sensitivity in tumor stem cell assay. Journ Neurosurg 66.3: 405–408, 1987
Olson JJ, Beck DW, Schlechte JA, Loh PM: Effect of anti-progesterone RU-38486 on meningioma implanted in nude mice. Journ Neurosurg 66.4: 584, 1987
Lesch KP, Schott W, Engl HG, Gross S, Thierauf P: Steroid receptors in meningioma. Journ Neurol 234.5: 328–333, 1987
Tilzner LL, Plapp FU, Evans JP, Stonedkell YA: Steroid receptors in human meningiomas. Cancer 49: 633–636, 1982
Fabian C, Sternso NL, Barnett M: Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedule. Canc Treat Rep 64: 65–773, 1980
Blakenstein MA, Vandermeulen-Dijk C, Thijssen JH: Effect of steroids and anti-steroids on human meningioma cells and primary culture. Journ Ster Biochem 34.1–6: 419–421, 1989
Adams EF, Schrell UM, Fahlbusch R, Thierauf P: Hormonal dependency of cerebral meningiomas (Part II):in vitro effects of steroids, bromocriptine and epidermal growth factor on growth of meningiomas. Journ Neurosurg 73.5: 750–755, 1990
Schrell UM, Fahlbusch R: Hormonal manipulation of cerebral meningiomas. In: Al-Mefty O (ed) Meningiomas, Raven Press, Ltd, New York, 1991
Grunberg SM, Weiss MH: Lack of efficacy of megestrol acetate in the treatment of unresectable meningiomas. Journ N Oncol 8: 61–65, 1990
Olson JJ, Beck DW, Schlechte J, Loh PM: Hormonal manipulation of meningiomasin vitro. Journ Neurosurg 65: 99–107, 1986
Markwalder TM, Seiler RW, Zavad T: Anti-estrogen therapy of meningiomas —a pilot study. Surg Neurol 24: 245–249, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Goodwin, J.W., Crowley, J., Eyre, H.J. et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study. J Neuro-Oncol 15, 75–77 (1993). https://doi.org/10.1007/BF01050266
Issue Date:
DOI: https://doi.org/10.1007/BF01050266